FDA Accepts Karyopharm sNDA for XPOVIO (selinexor) Plus Ruxolitinib in Myelofibrosis; PDUFA Date June 28, 2027
The FDA accepted Karyopharm's supplemental New Drug Application for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, with a Prescription Drug User Fee Act target action date of June 28, 2027. The sNDA is based primarily on the Phase 3 SENTRY trial (XPORT-MF-034), which randomized 353 JAK inhibitor-naive patients 2-to-1 to once-weekly 60 mg selinexor plus ruxolitinib versus placebo plus ruxolitinib, with co-primary endpoints of SVR35 at week 24 and average change in absolute total symptom score over 24 weeks...
Key takeaways
FDA accepted the sNDA for selinexor plus ruxolitinib in myelofibrosis; PDUFA target action date is June 28, 2027.
sNDA is based primarily on results from the Phase 3 SENTRY trial (XPORT-MF-034, NCT04562389), presented at the 2026 ASCO Annual Meeting and published in the Journal of Clinical Oncology.
SENTRY randomized 353 JAK inhibitor-naive myelofibrosis patients 2-to-1 to once-weekly 60 mg selinexor plus ruxolitinib vs. placebo plus ruxolitinib, in patients with platelet counts > 100 x 10^9/L.
Co-primary endpoints are spleen volume reduction of at least 35% (SVR35) at week 24 and average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline.
SENTRY results were also presented at the 2026 European Hematology Association Congress, where the presentation was recognized as one of six best abstracts.
Myelofibrosis affects approximately 20,000 patients in the United States and 19,000 patients in the European Union; JAK inhibitors are the only approved therapy class.
Company entered a Restructuring Support Agreement with lenders, noteholders and Ayrmid Ltd. on November 2, 2026 and filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas; the Ayrmid merger is expected to close in the first quarter of 2027.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow KPTI in real time
Get material earnings, filing, IR, and earnings-call alerts by email.